Biofortification with ZnO NPs as nanofertilizers to improve sustainable commercial and phytochemical quality in basil plants

Biofortification is the process of developing a crop with bioavailable micronutrients in its edible parts. This has been done using nanofertilizers, since they can be used to feed plants in a gradual and controlled manner. Therefore, the aim of this work was to evaluate the effect of foliar application of ZnO NPs in different concentrations on the commercial and phytochemical quality of the basil (Ocimum basilicum L.) crop, as it is one of the most important aromatic plants used for chemical and pharmacological properties. Four concentrations of ZnO NPs (5, 10, 15 and 20 mg L-1) and a control treatment under a completely randomized design, were evaluated. The results show statistical differences in morphological parameters (leaf and stem fresh weight, height, number of leaves, leaf area and dry weight) with a slight tendency to increase on the treated basil plants mainly at concentration of 20 mg L-1. The highest chlorophyll content (5.54 µg g-1 FW) was obtained for the control treatment, whereas the lowest one (4.14 µg g-1 FW) was observed for the 20 mg L-1 treatment. However, carotenoid content in the leaves was markedly higher than the control, the control had the concentration of 0.84 µg g-1 FW, while the treatment with 20 mg L-1 ZnO NPs registered a value of 1.08 µg g-1 FW. The highest total phenolic, flavonoid, antioxidant capacity and vitamin C content was obtained for 20 mg L-1 ZnO NPs. Finally, basil plants treated with ZnO NPs could stimulate enzymatic activity, as demonstrated in this study. Detailed studies are suggested to understand the mechanism of action of nanoscale materials

Outcomes from elective colorectal cancer surgery during the SARS-CoV-2 pandemic

This study aimed to describe the change in surgical practice and the impact of SARS-CoV-2 on mortality after surgical resection of colorectal cancer during the initial phases of the SARS-CoV-2 pandemic

International Nosocomial Infection Control Consortiu (INICC) report, data summary of 43 countries for 2007-2012. Device-associated module

We report the results of an International Nosocomial Infection Control Consortium (INICC) surveillance study from January 2007-December 2012 in 503 intensive care units (ICUs) in Latin America, Asia, Africa, and Europe. During the 6-year study using the Centers for Disease Control and Prevention's (CDC) U.S. National Healthcare Safety Network (NHSN) definitions for device-associated health care–associated infection (DA-HAI), we collected prospective data from 605,310 patients hospitalized in the INICC's ICUs for an aggregate of 3,338,396 days. Although device utilization in the INICC's ICUs was similar to that reported from ICUs in the U.S. in the CDC's NHSN, rates of device-associated nosocomial infection were higher in the ICUs of the INICC hospitals: the pooled rate of central line–associated bloodstream infection in the INICC's ICUs, 4.9 per 1,000 central line days, is nearly 5-fold higher than the 0.9 per 1,000 central line days reported from comparable U.S. ICUs. The overall rate of ventilator-associated pneumonia was also higher (16.8 vs 1.1 per 1,000 ventilator days) as was the rate of catheter-associated urinary tract infection (5.5 vs 1.3 per 1,000 catheter days). Frequencies of resistance of Pseudomonas isolates to amikacin (42.8% vs 10%) and imipenem (42.4% vs 26.1%) and Klebsiella pneumoniae isolates to ceftazidime (71.2% vs 28.8%) and imipenem (19.6% vs 12.8%) were also higher in the INICC's ICUs compared with the ICUs of the CDC's NHSN